(Reuters) – The U.S. Food and Drug Administration on Tuesday approved an updated version of Novavax’s protein-based COVID-19 vaccine for emergency use in people 12 and older, the health agency said.
The director of the U.S. Centers for Disease Control and Prevention (CDC) last month approved the widespread use of updated COVID-19 vaccines from Pfizer Inc. with German partner BioNTech SE and from Moderna for children ages six months and older for the fall vaccination campaign approved .
Novavax’s vaccination is based on older technology than messenger RNA vaccines.
(Reporting by Sriparna Roy in Bengaluru; Editing by Bill Berkrot)
Copyright 2023 Thomson Reuters.